Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium Therapy in Advanced Liver Cancer Immunotherapy
NCT05620004Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bifidobacterium bifidum in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Objective Response Rate at 1 year, Disease Control Rate at 1 year and 3 more. Status: unknown.
02
Drugs
bifidobacterium bifidum
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05620004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620004.